1. Home
  2. ENTX vs SCWO Comparison

ENTX vs SCWO Comparison

Compare ENTX & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.22

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$2.17

Market Cap

42.3M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
SCWO
Founded
2010
2021
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Environmental Services
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
58.2M
42.3M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
ENTX
SCWO
Price
$1.22
$2.17
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
57.3K
67.6K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$42,000.00
$215,037.00
Revenue This Year
N/A
$25,798.80
Revenue Next Year
N/A
N/A
P/E Ratio
$17.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.16
52 Week High
$3.22
$3.60

Technical Indicators

Market Signals
Indicator
ENTX
SCWO
Relative Strength Index (RSI) 48.48 42.13
Support Level $1.17 $0.26
Resistance Level $1.37 $2.84
Average True Range (ATR) 0.06 0.19
MACD -0.00 -0.03
Stochastic Oscillator 22.73 11.48

Price Performance

Historical Comparison
ENTX
SCWO

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About SCWO 374Water Inc.

374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.

Share on Social Networks: